Emergence of Rv0678 (mmpR5) mutations mediating resistance to bedaquiline and clofazimine in a liver transplant recipient with rifampicin-susceptible tuberculosis: A case report

Read full text Summarise with VIRAT
Authors: Jin Wang, Xiaomin Wang, Jiuxin Qu, Wenjie Lai, Yuxiang Wang, Xuelin Li, Shuihua Lu, Mutong Fang
Cited by: 0
References: 13

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Bedaquiline (Bdq) is a cornerstone therapeutic agent for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB), particularly in short-course regimens, and is currently under investigation for potential use in drug-susceptible tuberculosis. However, the emergence of Bdq-resistant TB strains has garnered global concern due to their profound impact on clinical treatment outcomes. Herein, we present the first documented case of a liver transplant recipient with rifampicin-susceptible pulmonary tuberculosis who developed concurrent resistance to both Bdq and clofazimine (Cfz). To mitigate hepatotoxicity and minimize drug-drug interactions, the patient's treatment was transitioned from a rifampicin-based regimen to a Bdq-containing regimen, co-administered with cycloserine (Cs), Cfz, and contezolid (Cte). Initial clinical responses were favorable, characterized by sputum culture conversion and radiographic improvement. However, at the four-month follow-up, sputum cultures reverted to positive, and pulmonary lesions demonstrated radiological progression. Whole-genome sequencing (WGS) analysis identified mutations in the Rv0678 gene (c.137dupG, c.144dupC, and c.58dupG), which were absent in pre-Bdq treatment isolates and are known to confer resistance to both Bdq and Cfz. Phenotypic drug susceptibility testing (DST) further confirmed susceptibility to Bdq and Cfz before Bdq exposure and resistance to both drugs after Bdq treatment. This case highlights the critical need for potent combination regimens during Bdq treatment, particularly among immunocompromised patients.

Fields of Study & Subjects

Tuberculosis Research and Epidemiology Antibiotic Resistance in Bacteria Infectious Diseases and Tuberculosis

Publication details

Journal / source
International Journal of Infectious Diseases
Volume
167
Pages
108587–108587
Publication date
26 March 2026
Language
EN